Literature DB >> 14669276

Prostate carcinoma tissue proteomics for biomarker discovery.

Yaxin Zheng1, Ye Xu, Bin Ye, Junyi Lei, Michael H Weinstein, Michael P O'Leary, Jerome P Richie, Samuel C Mok, Brian C-S Liu.   

Abstract

BACKGROUND: The advent of the prostate-specific antigen (PSA) test has had a profound impact on the diagnosis and treatment of prostate carcinoma. However, the use of PSA levels alone for screening for prostate carcinoma was compromised by the variations in the amount of PSA produced by the benign prostatic tissue specimens. Proteins were involved in various pathways that determine the behavior of a cell. Therefore, information regarding proteins may reveal drug targets and/or markers for early detection.
METHODS: The authors used surface-enhanced laser desorption/ionization time-of-flight mass spectrometry to determine the protein profiles from fresh tissues of the prostate. Laser capture microdissection was performed to isolate pure populations of cells.
RESULTS: The authors identified a protein with an average m/Z of 24,782.56 +/- 107.27 that was correlated with the presence of prostate carcinoma. Furthermore, using laser capture microdissection, they demonstrated that the origin of this protein, which the authors designated PCa-24, was derived from the epithelial cells of the prostate. PCa-24 expression was detected in 16 of 17 (94%) prostate carcinoma specimens but not in paired normal cells. In addition, this protein was not expressed in any of the 12 benign prostatic hyperplasia specimens that were assayed.
CONCLUSIONS: PCa-24 may be useful a marker for prostate carcinoma. Copyright 2003 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14669276     DOI: 10.1002/cncr.11849

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  16 in total

Review 1.  Prostate cancer detection strategies.

Authors:  Timothy C Brand; Javier Hernandez; Edith D Canby-Hagino; Joseph W Basler; Ian M Thompson
Journal:  Curr Urol Rep       Date:  2006-05       Impact factor: 3.092

2.  Choosing Therapy on the Basis of Disease Classifications in Inflammatory Bowel Disease.

Authors:  Maria T. Abreu
Journal:  Curr Treat Options Gastroenterol       Date:  2004-06

Review 3.  Personalized medicine and development of targeted therapies: The upcoming challenge for diagnostic molecular pathology. A review.

Authors:  Manfred Dietel; Christine Sers
Journal:  Virchows Arch       Date:  2006-04-22       Impact factor: 4.064

Review 4.  Laser capture microdissection: Big data from small samples.

Authors:  Soma Datta; Lavina Malhotra; Ryan Dickerson; Scott Chaffee; Chandan K Sen; Sashwati Roy
Journal:  Histol Histopathol       Date:  2015-04-20       Impact factor: 2.303

5.  Guidelines for the routine application of the peptide hits technique.

Authors:  Ji Gao; Mark S Friedrichs; Ashok R Dongre; Gregory J Opiteck
Journal:  J Am Soc Mass Spectrom       Date:  2005-08       Impact factor: 3.109

6.  Proteomic profiling of androgen-independent prostate cancer cell lines reveals a role for protein S during the development of high grade and castration-resistant prostate cancer.

Authors:  Punit Saraon; Natasha Musrap; Daniela Cretu; George S Karagiannis; Ihor Batruch; Chris Smith; Andrei P Drabovich; Dominique Trudel; Theodorus van der Kwast; Colm Morrissey; Keith A Jarvi; Eleftherios P Diamandis
Journal:  J Biol Chem       Date:  2012-08-20       Impact factor: 5.157

7.  Tissue profiling MALDI mass spectrometry reveals prominent calcium-binding proteins in the proteome of regenerative MRL mouse wounds.

Authors:  Robert L Caldwell; Susan R Opalenik; Jeffrey M Davidson; Richard M Caprioli; Lillian B Nanney
Journal:  Wound Repair Regen       Date:  2008-02-13       Impact factor: 3.617

8.  Methodology and applications of disease biomarker identification in human serum.

Authors:  Ziad J Sahab; Suzan M Semaan; Qing-Xiang Amy Sang
Journal:  Biomark Insights       Date:  2007-02-14

9.  Quantitative proteomics reveals that enzymes of the ketogenic pathway are associated with prostate cancer progression.

Authors:  Punit Saraon; Daniela Cretu; Natasha Musrap; George S Karagiannis; Ihor Batruch; Andrei P Drabovich; Theodorus van der Kwast; Atsushi Mizokami; Colm Morrissey; Keith Jarvi; Eleftherios P Diamandis
Journal:  Mol Cell Proteomics       Date:  2013-02-26       Impact factor: 5.911

10.  Marked improvement of cytotoxic effects induced by docetaxel on highly metastatic and androgen-independent prostate cancer cells by downregulating macrophage inhibitory cytokine-1.

Authors:  M Mimeault; S L Johansson; S K Batra
Journal:  Br J Cancer       Date:  2013-02-28       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.